The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Disease Pathways and Novel Therapeutic Targets in Hypertrophic Cardiomyopathy
Abstract
As described in earlier reviews in this series on the molecular basis of hypertrophic cardiomyopathy (HCM), HCM is one of the archetypal monogenic cardiovascular disorders to be understood at the molecular level. Twenty years after the discovery of the first HCM disease gene, genetic studies still confirm that HCM is principally a disease of the sarcomere. At the biophysical level, myofilament mutations generally enhance Ca 2+ sensitivity, maximal force production, and ATPase activity. These defects ultimately appear to converge on energy deficiency and altered Ca 2+ handling as major common paths leading to the anatomic (hypertrophy, myofiber disarray, and fibrosis) and functional features (pathological signaling and diastolic dysfunction) characteristic of HCM. In this review, we provide an account of the consequences of HCM mutations and describe how specifically targeting these molecular features has already yielded early promise for novel therapies for HCM. Although substantial efforts are still required to understand the molecular link between HCM mutations and their clinical consequences, HCM endures as an exemplar of how novel insights derived from molecular characterization of Mendelian disorders can inform the understanding of biological processes and translate into rational therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hypertrophic Cardiomyopathy: A Systematic Review
Maron, B. J. (2002) · JAMA · doi:10.1001/jama.287.10.1308 · Cited by 2,224
Cardiac-Resynchronization Therapy for Mild-to-Moderate Heart Failure
Tang, A. S. L., Wells, G. A., Talajic, M., Arnold, M. O., Sheldon, R., Connolly, S., Hohnloser, S. H., Nichol, G., Birnie, D. H., Sapp, J. L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1009540 · Cited by 1,859
Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy
Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C. C., Veres, G., Schmidt, M., Kutschera, I., Vidaud, M., Abel, U., Dal-Cortivo, L., Caccavelli, L., et al. (2009) · Science · doi:10.1126/science.1171242 · Cited by 1,508
Patient-Specific Induced Pluripotent Stem-Cell Models for Long-QT Syndrome
Moretti, A., Bellin, M., Welling, A., Jung, C. B., Lam, J. T., Bott-Flügel, L., Dorn, T., Goedel, A., Höhnke, C., Hofmann, F., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908679 · Cited by 1,251
Analysis of Genetic Inheritance in a Family Quartet by Whole-Genome Sequencing
Roach, J. C., Glusman, G., Smit, A. F. A., Huff, C. D., Hubley, R., Shannon, P. T., Rowen, L., Pant, K. P., Goodman, N., Bamshad, M., et al. (2010) · Science · doi:10.1126/science.1186802 · Cited by 1,084
Whole-Genome Sequencing in a Patient with Charcot–Marie–Tooth Neuropathy
Lupski, J. R., Reid, J. G., Gonzaga-Jauregui, C., Rio Deiros, D., Chen, D. C. Y., Nazareth, L., Bainbridge, M., Dinh, H., Jing, C., Wheeler, D. A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908094 · Cited by 759
Cardiac Troponin I Phosphorylation Increases the Rate of Cardiac Muscle Relaxation
Zhang, R., Zhao, J., Mandveno, A., & Potter, J. D. (1995) · Circulation Research · doi:10.1161/01.res.76.6.1028 · Cited by 322
Spindler, M., Saupe, K. W., Christe, M. E., Sweeney, H. L., Seidman, C. E., Seidman, J. G., & Ingwall, J. S. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1940 · Cited by 268
Cited by
The pathogenesis of cardiac fibrosis
Kong, P., Christia, P., & Frangogiannis, N. G. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1349-6 · Cited by 1,567
TGF-β-Induced Endothelial-Mesenchymal Transition in Fibrotic Diseases
Pardali, E., Sanchez-Duffhues, G., Gomez-Puerto, M., & Ten Dijke, P. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102157 · Cited by 360
Olivotto, I., Cecchi, F., Poggesi, C., & Yacoub, M. H. (2012) · Circulation: Heart Failure · doi:10.1161/circheartfailure.112.967026 · Cited by 352
Mechanisms of disease: hypertrophic cardiomyopathy
Frey, N., Luedde, M., & Katus, H. A. (2012) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.159 · Cited by 235
Advances in the Genetic Basis and Pathogenesis of Sarcomere Cardiomyopathies
Yotti, R., Seidman, C. E., & Seidman, J. G. (2019) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-083118-015306 · Cited by 168
Metadata
- Authors
- Ashrafian, H., McKenna, W. J., & Watkins, H.
- Venue
- Circulation Research
- Published
- 2011-06-24
- Volume
- 109
- Issue
- 1
- Pages
- 86-96
- ISSN
- 0009-7330 (ISSN-L)
- 1524-4571
- OpenAlex
- W1984606352
- Cited by
- 170
- References
- 8
- FWCI
- 10.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Disease Pathways and Novel Therapeutic Targets in Hypertrophic Cardiomyopathy. https://app.cochat.ai/papers/10.1161/circresaha.111.242974
- The paper
- Ashrafian, H., McKenna, W. J., & Watkins, H. (2011). Disease Pathways and Novel Therapeutic Targets in Hypertrophic Cardiomyopathy. Circulation Research. https://doi.org/10.1161/circresaha.111.242974
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.